What is the clinical evidence from this study?

Study design: Observational. Population: Hypertension (n=150). Intervention: Hypertension. Primary outcome: Platelet PAR4 expression and activation.

What question did this study set out to answer?

To investigate the mechanism by which G protein-coupled receptor PAR4 drives platelet hyperreactivity and arterial thrombosis in hypertensive conditions.

July 30, 2026European Heart JournalOpen Access

Angiotensin II-driven TGF-β1 increases platelet PAR4 expression enhancing thrombotic risk in hypertension

View Full Paper

Ask AI

Bookmark

Key result

Valsartan reverses hypertension-linked thrombotic risk by blocking Angiotensin II-driven platelet PAR4 expression.

n=150

Why the study?

Hypertensive patients have heightened pro-thrombotic susceptibility, but the mechanisms by which G protein-coupled receptors contribute to platelet hyperreactivity remain unclear.

Does valsartan reduce platelet PAR4 expression and thrombus formation in hypertension?

Population

150 hypertensive patients, spontaneously hypertensive rats, and L-NAME-induced hypertensive mice

Comparison

Hypertensive models and patients vs controls, plus PAR4- and TGF-beta 1-deficient models and valsartan

Design

Translational and mechanistic preclinical study with human observational cohort

Authors

MWMingzhu WangShanghai University of Traditional Chinese Medicine ZLZixian LiuHebei Agricultural University YCYufei ChenShanghai University of Traditional Chinese Medicine

Discussion

Member takes

Implication

Hypothesis-generating for valsartan's antithrombotic effects via PAR4 in hypertensive models; leaves open human translation.

Key Points

To investigate the mechanism by which G protein-coupled receptor PAR4 drives platelet hyperreactivity and arterial thrombosis in hypertensive conditions.
Analyzed platelet GPCR expression via RNA-seq and flow cytometry in 150 hypertensive patients, spontaneously hypertensive rats, and L-NAME-induced hypertensive mice.
Assessed platelet activation and thrombus formation using in vivo, ex vivo, and in vitro models with PAR4-deficient and TGF-β1-deficient mice.
Platelet PAR4 expression was elevated in hypertensive humans and animal models, positively correlating with integrin αⅡbβ3 activation and P-selectin exposure.
Angiotensin II induced TGF-β1 and activated Smad2 to bind the PAR4 promoter, upregulating PAR4 transcription and driving arterial thrombus formation through Gq and G12/13 signaling.
Valsartan, an angiotensin receptor blocker, reversed PAR4 overexpression and significantly attenuated thrombus formation in hypertensive models.

Study Design

Type

Observational (n=150)

Structured PICO

Does valsartan reduce platelet PAR4 expression and thrombus formation in hypertension?

Population

150 hypertensive patients, alongside rat and mouse models, evaluated for platelet GPCR expression and PAR4-mediated thrombotic risk.

Exposure

Valsartan (angiotensin II receptor blocker) and mechanistic probes (Angiotensin II, TGF-β1)

Comparator

Normotensive controls and wild-type models

Outcome

Platelet PAR4 expression, platelet activation (integrin αⅡbβ3 activation and P-selectin exposure), and arterial thrombus formationsurrogate

Valsartan exhibits a pleiotropic antithrombotic effect in hypertension by reversing Angiotensin II-driven, TGF-β1-mediated upregulation of platelet PAR4 expression.

Cite This Study

Wang et al. (2026) conducted an observational in Hypertension (n=150). Hypertension was evaluated on Platelet PAR4 expression and activation. Hypertension increases platelet PAR4 expression via Angiotensin II-driven TGF-β1 to enhance thrombotic risk, an effect that is reversed by valsartan.

synapsesocial.com/papers/6a9cd79e18679b9e3782cf6a https://doi.org/10.1093/eurheartj/ehag632

View Full Paper

Ask AI

Bookmark

Angiotensin II-driven TGF-β1 increases platelet PAR4 expression enhancing thrombotic risk in hypertension

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Cite This Study

Angiotensin II-driven TGF-β1 increases platelet PAR4 expression enhancing thrombotic risk in hypertension

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Cite This Study

Also Consider

Also Consider